# Jason Gammack

> Jason T. Gammack is a biotechnology executive, founder, investor, and adviser with more than three decades in life-science tools. After senior commercial roles at Promega, Affymetrix, Invitrogen/Life Technologies, Sigma-Aldrich, Ingenuity Systems, QIAGEN, and Inscripta, he co-founded and led spatial-biology company Resolve Biosciences. Since February 2024 he has served as CEO of Ansa Biotechnologies, where his commercial thesis is that complex synthetic DNA should arrive as predictably as any ordinary laboratory reagent. Under his leadership, Ansa introduced an on-time guarantee, launched sequence-verified clonal DNA products extending to 50 kilobases, raised a $54.4 million Series B, and formed a distribution collaboration with Integrated DNA Technologies.

- **Role:** Chief Executive Officer at Ansa Biotechnologies, Inc.
- **Organizations:** Ansa Biotechnologies, Inc., JTG Investments & Advisory UG, Resolve Biosciences, Inscripta, QIAGEN, Ingenuity Systems, Sigma-Aldrich, Invitrogen/Life Technologies, Affymetrix, Promega Corporation
- **Education:** B.S., Iowa State University, Ph.D., University of Washington
- **Known for:** Co-founded Resolve Biosciences and helped launch its highly multiplexed Molecular Cartography spatial-analysis platform., Led Resolve Biosciences as it raised a $71 million Series B in 2022., Built commercialization programs for genomics and gene-editing tools across QIAGEN and Inscripta.

## Career timeline

- **1990s-2013** — Built a career in life-science products and commercialization, including senior roles at Promega, Affymetrix, Invitrogen/Life Technologies, Sigma-Aldrich, and Ingenuity Systems.
- **2013-2018** — Continued at QIAGEN after its acquisition of Ingenuity Systems, ultimately serving as vice president of the life science business and leading portfolio and go-to-market strategy.
- **2018-2020** — Served as Inscripta's first chief commercial officer, overseeing sales, marketing, business development, and customer support for its CRISPR-enabled Onyx platform.
- **2020** — Co-founded Resolve Biosciences and became CEO, bringing its Molecular Cartography spatial-analysis platform to market.
- **2022** — Led Resolve Biosciences through a $71 million Series B financing for commercial expansion.
- **2023** — Left Resolve Biosciences during a CEO transition and founded JTG Investments & Advisory UG.
- **2024** — Joined Ansa Biotechnologies as CEO as founding CEO Dan Lin-Arlow moved to the chief scientific officer role.
- **2025** — Led Ansa's commercial push around an on-time guarantee, the launch of sequence-verified clonal DNA up to 50 kb, and a $54.4 million Series B financing.
- **2026** — Ansa announced a strategic collaboration with Integrated DNA Technologies to make its Clonal DNA and XL Clonal DNA products available to IDT customers.

## Achievements

- Co-founded Resolve Biosciences and helped launch its highly multiplexed Molecular Cartography spatial-analysis platform.
- Led Resolve Biosciences as it raised a $71 million Series B in 2022.
- Built commercialization programs for genomics and gene-editing tools across QIAGEN and Inscripta.
- Oversaw Ansa Biotechnologies' transition from early access toward full commercial service.
- Introduced Ansa's on-time guarantee for complete synthetic DNA orders.
- Led Ansa during the launch of sequence-verified clonal DNA products extending to 50 kb and its $54.4 million Series B financing.
- Expanded Ansa's commercial reach through a 2026 collaboration with Integrated DNA Technologies.

## Latest updates

- **2026-05** — Presented Ansa's case for AI-enabled design and complex DNA synthesis at SynBioBeta 2026 and joined a panel on breaking DNA-synthesis barriers.
- **2026-04** — Argued in a SynBioBeta interview that many accepted DNA design constraints are artifacts of legacy manufacturing rather than laws of nature.
- **2026-01** — Ansa and Integrated DNA Technologies announced a collaboration to offer Ansa's clonal and XL clonal DNA products to IDT customers.
- **2025-12** — Ansa detailed its ultra-long clonal DNA service, including constructs up to 50 kb and guaranteed delivery targets.
- **2025-10** — Ansa secured $54.4 million in Series B financing to expand U.S. DNA manufacturing capacity.

## Links

- Website: https://ansabio.com
- LinkedIn: https://www.linkedin.com/in/jasontgammack
- Twitter/X: https://twitter.com/AnsaBio
- YouTube: https://www.youtube.com/@ansabio

---

Profile page: https://yespress.io/jason-gammack
Published by YesPress — https://yespress.io
Last updated: 2026-08-17